Healthcare

For a company that spent years teaching the market patience, Alcidion Group is moving faster. On 19 August the health-informatics software developer will release its FY26 accounts, and the result arrives after the busiest twelve months in the company's history. A landmark National Health …

OncoSil Medical (ASX:OSL) has reached a major regulatory milestone after the U.S. Food and Drug Administration granted Humanitarian Device Exemption approval for its OncoSil device for the treatment of distal cholangiocarcinoma (dCCA). The approval follows the completion of the company's HDE regulatory process and …

Australian Clinical Labs Limited (ASX:ACL) reported a mixed FY26 financial performance, with revenue declining 0.7% while underlyingEarningsincreased. The company's underlying EBIT rose 1.7%, accompanied by a 20-basis-point expansion in the underlying EBIT margin.

Australian Clinical Labs Limited (ASX:ACL) reported a mixed FY26 financial performance, with revenue declining 0.7% while underlyingEarningsincreased. The company's underlying EBIT rose 1.7%, accompanied by a 20-basis-point expansion in the underlying EBIT margin.

What is clear is the timing: Healius is due to hand down its full-year FY26 results on Wednesday, 19 August 2026, alongside an investor webcast at 10:30am AEST. With the stock still trading near record lows and a strategic review of the company'sAssetsunder way, …

CLEO is a pre-revenue diagnostics developer working toward US regulatory clearance for a blood test designed to assess ovarian cancer risk before surgery. No confirmed company-specific announcement around 14 August 2026 explains this particular day's decline, so this article focuses on verified recent developments, …

Emyria (ASX:EMD) is a healthcare company focused on psychedelic-assisted therapy and mental-health services through its Empax clinic network. The company is developing a revenue-generating healthcare model by providing patient treatments while continuing to build clinical data and regulatory capabilities.